



### PATIENTS CAN DO IT REMOTELY

# AGP REPORT WITH TIME IN RANGE







Abbott

The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in adults aged 18 years and older with diabetes mellitus. Always read and follow the label/insert.

#### AGP, ambulatory glucose profile.

LibreView is developed, distributed, and supported by Newyu, Inc. The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.

# Look beyond A1C for the real story behind your patients' glucose results

### A1C has limitations

A1C reflects average glucose over the last 2-3 months; it does not show glycemic excursions of hyper- and hypoglycemia<sup>1</sup>





Time In Range helps you to quickly assess patients' glucose control and contextualize A1C by showing the percentage of readings and time per day in and out of range




Every 10% increase in Time In Range = ~0.8% decrease in A1C<sup>2</sup>

References: 1. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. *Diabetes Care.* 2019;42(8):1593-1603. 2. Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. *Diabetes Technol Ther.* 2019;21(2):81-85.

## Easily identify glucose patterns and trends in a single-page comprehensive report

### The new report shows:



FLASH GLUCOSE MONITORING SYSTEM

# See guidelines for Time In Range targets and an overview of patient glucose data

**GLUCOSE STATISTICS AND TARGETS** 

#### Glucose Management Indicator (GMI)

GMI indicates what the patient's approximate A1C level is likely to be, based on the average glucose level from sensor technology readings of 14 or more days

#### **Glucose Variability**

The glucose variability is how far the patient's readings are from their average glucose level

28 February 2020 - 12 March 2020 % Time CGM is Active	14 Days 97%			
Ranges And Targets For	Type 1 or Type 2 Diabetes			
Glucose Ranges Target Range 3.9-10.0 mmol/L	<b>Targets</b> % of Readings (Time/Day) Greater than 70% (16h 48min)			
Below 3.9 mmol/L	Less than 4% (58min)			
Below 3.0 mmol/L	Less than 1% (14min)			
Above 10.0 mmol/L	Less than 25% (6h)			
Above 13.9 mmol/L	Less than 5% (1h 12min)			
Each 5% increase in time in range (3.9-10.0 mmol/L) is clinically beneficial.				
Average Glucose	<b>7.8</b> mmol/L			
Glucose Management Indicator (GMI) 6.7% or 49 mm				
Glucose Variability	32.1%			
Defined as percent coefficient of variation (%CV); target ≤36%				

The **recommended Time In Ranges** for adult patients with type 1 or type 2 diabetes who are not pregnant, older, or at risk are provided in this section of the report<sup>1</sup>



For illustrative purposes only. Not actual patient data. **Reference: 1.** Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. *Diabetes Care.* 2019;42(8):1593-1603.

### Quickly assess your patients' Time In Ranges

2				]
	TIME IN R	ANGES		
		_ Very High >13.9 mmol/L	<b>1%</b> (14min)	% of time above
	13.9	<b>High</b> 10.1 - 13.9 mmol/L	<b>18%</b> (4h 19min)	target range
	10.0			
		Target Range 3.9 - 10.0 mmol/L	<b>78%</b> (18h 44min)	% of time within target range
	3.9 3.0	<b>Low</b> 3.0 - 3.8 mmol/L	<b>3%</b> (43min)	% of time below
	└── Very Lo	- Very Low <3.0 mmol/L	<b>0%</b> (0min)	target range



The primary goal for effective and safe glucose control is to increase Time In Range while reducing Time Below Range<sup>1</sup>

For illustrative purposes only. Not actual patient data.


Reference: 1. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603.

# The AGP makes it easy to identify trends and patterns at a glance

#### AMBULATORY GLUCOSE PROFILE (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day.

Uncover patterns of hyper- and hypoglycemia and see glycemic variability 3






### AGP when used with Time In Range can reveal when patients are out of their range

AGP, ambulatory glucose profile. The AGP requires a minimum of 5 days of glucose data to generate reports and can use a maximum of 90 days of data. For illustrative purposes only. Not actual patient data.

# Identify specific times of deviation with the Daily Glucose Profiles




A way for you and your patients to **see specific daily glucose activity,** which could help identify causes for deviations from Time In Range



Use these daily glucose values profiles to help guide your patients through a clinical and engaging dialogue





### Make more informed diabetes management decisions\* with the new AGP report

- Time In Range allows you to quickly assess your patients' time spent above, within, and below target range
- AGP graph helps you see when the patient is out of range
- Identify glucose trends and patterns at a glance



Help your patients increase their Time In Range Prescribe the FreeStyle Libre system



Abbott

\* Treatment decisions should not be based on real-time sensor glucose readings alone and instead should consider all the information on the results screen.

For illustrative purposes only. Not actual patient data.

© 2020 Abbott. FreeStyle, Libre, and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions. Product images are for illustrative purposes only. Other trademarks are the property of their respective owners. ADC-21126